Privi Speciality Chemicals
Privi Speciality Chemicals
ChemicalsKey Fundamentals
MicrocapSpecialty ChemicalsChemicalsTapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Company has delivered good profit growth of 26.8% CAGR over last 5 years
Weaknesses
2- Stock is trading at 9.84 times its book value
- Promoter holding has decreased over last 3 years: -13.4%
Growth Rate
AI Analysis — Bull vs Bear
Privi Speciality Chemicals trades at a market cap of Rs 13,782 crore with a PE of 40.9x and PB of 9.9x. The company has delivered strong profit growth of 61% TTM and 144% CAGR over 3 years, while the stock has appreciated 48% over the last year. Promoter holding has declined by 13.4% over three years, and valuations remain elevated relative to book value.
- TTM profit growth of 61% indicates strong earnings momentum and operational leverage
- 3-year compounded profit CAGR of 144% reflects a dramatic earnings turnaround
- Last year ROE of 26% is well above the 5-year average of 15%, showing improving capital efficiency
- 5-year compounded profit CAGR of 27% demonstrates sustained long-term earnings delivery
- TTM sales growth of 22% suggests healthy topline expansion and demand visibility
- Stock CAGR of 28% over 10 years indicates consistent long-term wealth creation
- 5-year compounded sales CAGR of 15% shows steady revenue scaling in the specialty chemicals space
- 3-year ROE average of 19% comfortably exceeds cost of equity for most chemical companies
- Stock trades at 9.91x book value, which is expensive relative to specialty chemical peers
- PE of 40.9x leaves little room for execution missteps or margin compression
- Promoter holding has decreased by 13.4% over 3 years, signaling potential dilution or reduced promoter confidence
- Dividend yield of just 0.28% offers minimal income cushion in a downturn
- 3-year stock CAGR of 52% far outpaces 3-year sales CAGR of 17%, suggesting valuation has run ahead of fundamentals
- 10-year compounded sales and profit growth data is incomplete, limiting long-cycle visibility
- 1-year stock CAGR of 48% versus TTM sales growth of 22% implies market is pricing in forward growth that may not materialize
- Debt-to-equity ratio is unavailable, making it difficult to assess balance sheet leverage and financial risk
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
- Strong Q1 profit growth Jul 30
Standalone net profit rose 22.7% YoY to ₹84.26 crore in Q1FY26; consolidated net profit surged 43.9% YoY to ₹82.84 crore, driven by higher revenue.
- ₹10 final dividend declared Aug 7
Board declared a final dividend of ₹10 per share for FY26 at the 41st AGM held on August 7, 2026, signaling confidence in cash flows.
- Investor meet scheduled Aug 18 Aug 11
Privi scheduled an analyst and institutional investor meeting for August 18, 2026, in Mumbai, organized by MOSL, covering publicly available information.
- Q1 FY27 earnings call planned Jul 23
Management will host an earnings call on July 31, 2026, to discuss Q1 FY27 operational and financial results.
TL;DR: Privi Speciality Chemicals is delivering solid earnings momentum with over 22% standalone and 43% consolidated profit growth in Q1, supported by a healthy ₹10 dividend. No material headwinds are visible in recent news flow. The upcoming investor meet and earnings call should provide further clarity on whether this growth trajectory is sustainable into FY27.
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 409 | 455 | 404 | 484 | 464 | 533 | 491 | 614 | 559 | 679 | 605 | 722 | 666 |
| Expenses | 354 | 366 | 314 | 393 | 370 | 423 | 378 | 481 | 427 | 497 | 453 | 541 | 514 |
| Operating Profit | 55 | 89 | 90 | 91 | 94 | 110 | 113 | 133 | 132 | 182 | 151 | 180 | 152 |
| OPM % | 13% | 20% | 22% | 19% | 20% | 21% | 23% | 22% | 24% | 27% | 25% | 25% | 23% |
| Other Income | 6 | 7 | 6 | 8 | 3 | 4 | 2 | 15 | 9 | 0 | 7 | 4 | 15 |
| Interest | 24 | 25 | 24 | 25 | 22 | 22 | 22 | 23 | 24 | 21 | 19 | 18 | 17 |
| Depreciation | 31 | 31 | 32 | 30 | 32 | 32 | 32 | 35 | 36 | 36 | 36 | 36 | 37 |
| PBT | 6 | 40 | 39 | 44 | 43 | 61 | 61 | 90 | 81 | 125 | 104 | 130 | 113 |
| Tax % | 30% | 25% | 26% | 28% | 27% | 26% | 27% | 29% | 29% | 28% | 28% | 27% | 27% |
| Net Profit | 5 | 30 | 29 | 32 | 31 | 45 | 44 | 64 | 58 | 90 | 75 | 94 | 83 |
| EPS in Rs | 1.18 | 7.8 | 7.36 | 7.93 | 8.02 | 11.42 | 11.37 | 17.01 | 15.84 | 24.02 | 19.95 | 23.96 | 21.54 |
Profit & Loss
| Particulars | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 597 | 1,024 | 1,341 | 1,631 | 1,277 | 1,404 | 1,608 | 1,752 | 2,101 | 2,564 | 2,671 |
| Expenses | 525 | 894 | 1,128 | 1,362 | 1,067 | 1,209 | 1,420 | 1,423 | 1,643 | 1,912 | 2,005 |
| Operating Profit | 72 | 130 | 213 | 268 | 210 | 195 | 188 | 329 | 458 | 651 | 666 |
| OPM % | 12% | 13% | 16% | 16% | 16% | 14% | 12% | 19% | 22% | 25% | 25% |
| Other Income | 10 | 16 | 14 | 66 | 43 | 38 | 21 | 26 | 20 | 19 | 26 |
| Interest | 20 | 24 | 29 | 41 | 24 | 25 | 70 | 102 | 92 | 87 | 75 |
| Depreciation | 27 | 43 | 47 | 63 | 71 | 75 | 108 | 123 | 132 | 144 | 145 |
| PBT | 36 | 79 | 152 | 231 | 158 | 133 | 31 | 130 | 255 | 440 | 472 |
| Tax % | 24% | 32% | 38% | 24% | 26% | 27% | 31% | 27% | 27% | 28% | — |
| Net Profit | 27 | 53 | 94 | 176 | 117 | 97 | 21 | 95 | 185 | 317 | 342 |
| EPS in Rs | 7.21 | 14.19 | 24.1 | 45.1 | 29.9 | 24.91 | 5.68 | 24.27 | 47.83 | 83.77 | 89.47 |
| Div. Payout % | 14% | 11% | 10% | 3% | 7% | 8% | 0% | 8% | 10% | 12% | — |
Balance Sheet
| Particulars | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 38 | 38 | 39 | 39 | 39 | 39 | 39 | 39 | 39 | 39 |
| Reserves | 406 | 451 | 537 | 702 | 683 | 773 | 790 | 885 | 1,064 | 1,373 |
| Borrowings | 321 | 330 | 491 | 569 | 537 | 933 | 1,079 | 1,008 | 1,143 | 1,021 |
| Other Liabilities | 174 | 235 | 359 | 294 | 281 | 431 | 483 | 410 | 544 | 736 |
| Total Liabilities | 939 | 1,053 | 1,426 | 1,604 | 1,540 | 2,176 | 2,391 | 2,343 | 2,791 | 3,170 |
| Fixed Assets | 388 | 437 | 498 | 725 | 598 | 704 | 1,017 | 1,034 | 1,156 | 1,169 |
| CWIP | 24 | 49 | 95 | 40 | 175 | 373 | 100 | 99 | 141 | 314 |
| Investments | 1 | 3 | 0 | 1 | 0 | 12 | 7 | 40 | 8 | 54 |
| Other Assets | 527 | 564 | 833 | 839 | 768 | 1,087 | 1,268 | 1,169 | 1,485 | 1,633 |
| Total Assets | 939 | 1,053 | 1,426 | 1,604 | 1,540 | 2,176 | 2,391 | 2,343 | 2,791 | 3,170 |
Cash Flow
| Particulars | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 17 | 107 | 21 | 247 | 172 | 5 | 49 | 354 | 281 | 550 |
| Investing | 80 | -81 | -139 | -206 | -242 | -321 | -133 | -180 | -294 | -358 |
| Financing | -89 | -20 | 122 | 27 | 0 | 333 | 72 | -171 | 39 | -198 |
| Net Cash Flow | 7 | 5 | 4 | 68 | -69 | 17 | -12 | 4 | 26 | -6 |
| Free Cash Flow | 17 | 107 | 46 | 37 | -71 | -304 | -91 | 212 | -17 | 230 |
| CFO/OP | 49 | 96 | 24 | 120 | 101 | 19 | 33 | 116 | 77 | 102 |
Ratios
| Particulars | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 106 | 82 | 90 | 60 | 68 | 69 | 67 | 72 | 68 | 75 |
| Inventory Days | 236 | 132 | 162 | 135 | 170 | 279 | 311 | 245 | 262 | 235 |
| Days Payable | 115 | 85 | 95 | 55 | 83 | 138 | 114 | 105 | 134 | 150 |
| Cash Conversion Cycle | 227 | 129 | 157 | 139 | 155 | 209 | 264 | 212 | 197 | 160 |
| Working Capital Days | 31 | 20 | 40 | 45 | 65 | 19 | 16 | 37 | 35 | 54 |
| ROCE % | — | 13% | 18% | 20% | 12% | 10% | 6% | 12% | 16% | 22% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Privi Speciality Chemicals insights
64 extracted metrics + investor summaries across FY10–FY27.
Documents
Frequently Asked Questions about Privi Speciality Chemicals
What does Privi Speciality Chemicals Ltd do?
Where is Privi Speciality Chemicals Ltd (PRIVISCL) listed?
Which sector does Privi Speciality Chemicals Ltd belong to?
What is the market capitalisation of Privi Speciality Chemicals Ltd?
What is the PE ratio of Privi Speciality Chemicals Ltd?
What is the 52-week high and low of Privi Speciality Chemicals Ltd?
Does Privi Speciality Chemicals Ltd pay dividends?
What is the Return on Equity (ROE) of Privi Speciality Chemicals Ltd?
Company Information
Incorporated in 1985, Privi Speciality Chemicals Ltd (Formerly known as Privi Speciality Ltd.) is primarily engaged in the manufacturing, supply and exports of aroma and fragrance chemicals used in soaps, detergents, shampoos, and other fine fragrances. [1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/PRIVISCL.md for Privi Speciality Chemicals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.